BioSyent Inc. RX

MISSISSAUGA, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named as one of Canada’s Top Growing Companies for 2026 by The Globe and Mail’s Report on Business magazine. BioSyent ranked 343 on the list based on its three-year revenue growth of 54% (2022 – 2025) and is listed in the ‘Consumer’ category. “We are very proud to have been recognized as one of Canada’s Top Growing Companies,” said René Goehr

MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include: (CAD)Q2 2026 % Changevs. Q2 2025 H1 2026 % Changevs. H1 2025 TTMJun 30, 2026 % Changevs. TTMJun 30, 2025 Pharmaceutical Sales11,110,365 +14% 21,913,472 +7% 42,325,508 +11% Oral Health Sales8,224,402 n/a 11,209,375 n/a 11,209,375

MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. This third quarter 2026 dividend compares to a second quarter dividend of $0.055 per common share. This dividend qualifies as an 'eligible dividend' f

MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Vent

MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT. Mr. Goehrum will also be meeting with investors on a one-on-one basis durin

MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada. “Having a

MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an 'eligible dividend' for Canadi

MISSISSAUGA, Ontario, May 07, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the first quarter ended March 31, 2026 on Thursday, May 14, 2026 after market hours. A presentation on the Company’s first quarter 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “

MISSISSAUGA, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX), a profitable growth-stage specialty healthcare products company, is pleased to announce that it will be presenting at the upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 21st and Wednesday, April 22nd, 2026. Mr. René Goehrum, President and CEO of BioSyent, will presen

MISSISSAUGA, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® has been named the #1 recommended over-the-counter (OTC) iron supplement brand in Canada based on a national survey of Canadian pharmacists and physicians. This achievement reinforces the brand leadership and trusted reputation of FeraMAX® among healthcare professionals nationwide, including those professionals in Quebec. For more than a decade, FeraMAX® has c

MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX

MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include: (CAD)Q4 2025 % Changevs.Q4 2024 FY 2025 % Change vs. FY 2024 Canadian Pharma Sales8,792,653 +3%37,143,783 +13%International Pharma Sales601,387 +240%3,735,959 +302%Legacy Business Sales277,883 +278%2,172,241 +86%Total Company Sales9,671,923 +10%43,051,983 +23%EBITDA